Active Ingredient History

NOW
  • Now
Clevidipine is a dihydropyridine calcium channel blocker. Clevidipine is marketed under the trade name Cleviprex, indicated for the reduction of blood pressure (BP) when oral therapy is not feasible or not desirable. Clevidipine is a dihydropyridine L-type calcium channel blocker. L-type calcium channels mediate the influx of calcium during depolarization in arterial smooth muscle. Experiments in anesthetized rats and dogs show that clevidipine reduces mean arterial blood pressure by decreasing systemic vascular resistance. Clevidipine does not reduce cardiac filling pressure (pre-load), confirming lack of effects on the venous capacitance vessels.   NCATS

  • SMILES: CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C1C2=CC=CC(Cl)=C2Cl)C(=O)OC
  • InChIKey: KPBZROQVTHLCDU-UHFFFAOYSA-N
  • Mol. Mass: 456.316
  • ALogP: 4.25
  • ChEMBL Molecule:
More Chemistry

Drug Pricing (per unit)

United States

$0.9053 - $45.7480
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

butyroxymethyl methyl 4-(2',3'-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate | clevelox | clevidipine | clevidipine butyrate | cleviprex

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue